T2
KAITLIN randomized patients after adriacymycin/cyclophosphamide to either paclitaxel/trastuzumab/pertuzumab or TDM-1/pertuzumab.
#bcsm
KAITLIN randomized patients after adriacymycin/cyclophosphamide to either paclitaxel/trastuzumab/pertuzumab or TDM-1/pertuzumab.
#bcsm
The two arms were nearly identical for primary endpoint IDFS, subsequently a “ negative “ trial. This trial raises all sorts of questions and controversies. Based on TRAIN-2, the administration of anthracycline to all patients likely could have been avoided #bcsm
Additionally, we have little data about the specific benefits of adding pertuzumab to TDM-1. #bcsm
But interestingly, the patient reports outcomes favored the TDM-1 containing arm with a HR of 0.71, which may be a signal that, if outcomes are the same, TDM-1 may offer a better tolerated treatment option for those with early stage Her2 positive breast cancer. #bcsm
That last point matters to me. We need to know how to better tailor Her2 treatment in early stage disease. #bcsm
• • •
Missing some Tweet in this thread? You can try to
force a refresh
